OKYO Pharma Ltd. Form 6-K Summary
Business Context and Reporting Period
OKYO Pharma Ltd., a foreign private issuer reporting on Form 20-F, furnished this Form 6-K on March 30, 2023. The filing reports an insider-related purchase of the company’s American depositary shares (ADSs).
Key Transaction and Financial Metrics
- Panetta Partners Limited purchased 11,000 OKYO ADSs on Nasdaq.
- The purchase price was US$1.41 per ADS, representing an aggregate purchase price of approximately US$15,510.
- Panetta Partners Limited is an entity in which Gabriele Cerrone, the company’s Executive Chairman, has a beneficial interest.
- The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating and financial metrics.
Material Changes, Outlook, and Risks
The filing does not report changes in operating performance, financial condition, guidance, business outlook, contingencies, or material risks. It solely furnishes the announcement regarding the ADS purchase.
The attached announcement is furnished, rather than filed, and is not subject to liability under Section 18 of the Securities Exchange Act of 1934 or incorporated by reference into other filings unless expressly stated.
Investor Verification Points
- Verify the 11,000-ADS purchase, the US$1.41 purchase price, and the beneficial relationship between Panetta Partners Limited and Gabriele Cerrone.
- Review Exhibit 99.1 for the complete transaction announcement.
- Consult the company’s periodic reports for financial results, liquidity, capital requirements, and operating outlook, which are not included in this Form 6-K.